Capstan Launches, Backed By Big Names And Big Pharma, To Pioneer In Vivo Cell Therapies
Focused on Combining mRNA and CAR technologies
The start-up, founded on science from the University of Pennsylvania, announced a $102m series A financing and the appointment of former Silverback CEO Laura Shawver as CEO.
You may also be interested in...
Kite CEO Christie Shaw said Tmunity brings three advantages: armored CAR-Ts, manufacturing technology and an ongoing research deal with the University of Pennsylvania.
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.